Literature DB >> 6179523

Interferon production in patients with systemic lupus erythematosus.

R M Friedman, O Preble, R Black, S Harrell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6179523     DOI： 10.1002/art.1780250717

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  6 in total

1.  Dosage of X-linked Toll-like receptor 8 determines gender differences in the development of systemic lupus erythematosus.

Authors:  Benjamin R Umiker; Shauna Andersson; Luis Fernandez; Parimal Korgaokar; Amma Larbi; Monika Pilichowska; Craig C Weinkauf; Henry H Wortis; John F Kearney; Thereza Imanishi-Kari
Journal:  Eur J Immunol       Date:  2014-03-20       Impact factor: 5.532

2.  Type I interferon correlates with serological and clinical manifestations of SLE.

Authors:  M C Dall'era; P M Cardarelli; B T Preston; A Witte; J C Davis
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

Review 3.  Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms.

Authors:  Xiaoyu Hu; Soumya D Chakravarty; Lionel B Ivashkiv
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

4.  Heterogeneous Escape from X Chromosome Inactivation Results in Sex Differences in Type I IFN Responses at the Single Human pDC Level.

Authors:  Sven Hendrik Hagen; Florian Henseling; Jana Hennesen; Hélène Savel; Solenne Delahaye; Laura Richert; Susanne Maria Ziegler; Marcus Altfeld
Journal:  Cell Rep       Date:  2020-12-08       Impact factor: 9.423

Review 5.  B-cell selection and the development of autoantibodies.

Authors:  Natalia V Giltiay; Craig P Chappell; Edward A Clark
Journal:  Arthritis Res Ther       Date:  2012-11-02       Impact factor: 5.156

Review 6.  Pathophysiology of cutaneous lupus erythematosus.

Authors:  Julie H Lin; Jan P Dutz; Richard D Sontheimer; Victoria P Werth
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 10.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.